AchE Inhibitor and Insulin

University of Miami12 enrolled

Overview

The investigator will examine the effect of a single dose of pyridostigmine, AchE inhibitor on insulin secretion in healthy subjects. Each subject will undergo an intravenous glucose tolerance test (IVGTT) where IV glucose will be administered and the glucose excursion and insulin secretion response will be evaluated by measuring insulin and glucose at different time points. The test will be carried out twice, once without and once with the administration of a single dose of Pyridostigmine on two separate days. The investigator hypothesizes that inhibiting AChE will potentiate insulin secretion.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Diabetes Mellitus

Interventions

PyridostigmineDRUG

single oral dose of 60 mg pyridostigmine tablet

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years and older Exclusion Criteria: * BMI \>30 Kg/m2 * fasting glucose \>100 * Glycohemoglobin (Hemoglobin A1C) 5.7% or more * History of asthma * Use of medications that may interfere with glucose metabolism

Locations (1)

Diabetes Research Institute

Miami, Florida, United States

Outcomes

Primary Outcomes

First phase insulin response to IV glucose infusion

Insulin positive incremental area under the curve and the sum of plasma insulin values at 1 minute and 3 minutes after IV glucose infusion

Time frame: -10, -4, 1, 2, 3, 4, 5, 6, 8, and 10 minutes

Secondary Outcomes

Glucose excursion after IV glucose infusion

Glucose positive incremental area under the curve

Time frame: -10, -4, 1, 2, 3, 4, 5, 6, 8, and 10 minutes

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.